Lupin rose 3.44% to Rs 1,724.95 at 15:25 IST on BSE, with the stock gaining on bargain hunting after falling 9.63% in preceding eight trading days to Rs 1,667.60 yesterday, 13 January 2016 from a recent high of Rs 1,845.50 on 1 January 2016.
Meanwhile, the BSE Sensex was down 76.74 points, or 0.31% to 24,777.37
On BSE, so far 87,338 shares were traded in the counter, compared with an average volume of 82,781 shares in the past one quarter. The stock hit a high of Rs 1,723.70 and a low of Rs 1,635.35 so far during the day. The stock had hit a record high of Rs 2,127 on 6 October 2015. The stock had hit a 52-week low of Rs 1,410 on 15 January 2015. The stock had underperformed the market over the past one month till 13 January 2016, falling 4.21% compared with 0.76% fall in the Sensex. The stock also underperformed the market in past one quarter, sliding 17.58% as against Sensex's 7.42% decline.
The large-cap company has an equity capital of Rs 90.10 crore. Face value per share is Rs 2.
Lupin's consolidated net profit dropped 35.1% to Rs 408.84 crore on 2% rise in net sales to Rs 3178.29 crore in Q2 September 2015 over Q2 September 2014.
Lupin is a pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Powered by Capital Market - Live News